As a clinician who has witnessed the devastating impact of the HIV/AIDS epidemic since the 1980s, Sheena McCormack is enthusiastic about her latest project, the UK Medical Research Council (MRC) PROUD study. As lead investigator, she has been investigating the effect of pre-exposure prophylaxis (PrEP) to protect against HIV infection in high-risk men who have sex with men (MSM). PROUD has shown that PrEP reduces new HIV infections by 86%.
28 March 2015 | The Lancet
UNAIDS is holding its first round of virtual consultations to develop its 2016–2021 Strategy. From 23 March to 2 April, the consultation process will be open to everyone to share information, ideas and experiences on how to accelerate rights-based, evidence-informed action to Fast-Track the AIDS response.
26 March 2015 | UNAIDS
Charging non-EU migrants for access to primary care would increase health risks to the rest of the population and place an even bigger financial burden on the NHS, experts from the London School of Hygiene and Tropical Medicine have warned.
24 March 2015 | Pulse
The English Government has revealed that £800,000 of new money will be spent on HIV prevention, and to reduce the numbers of late diagnoses. A new £500,000 innovation fund was unveiled, which has been administered by Public Health England (PHE), and will allow small organisations to bid for funding of up to £50,000.
13 March 2015 | Pink News
Officials from NIH and the city of Washington, D.C., launched a clinical trial to examine whether primary care physicians and other health care providers, such as nurse practitioners and physician assistants, can use a new antiviral therapy as effectively as specialist physicians to treat people with hepatitis C virus (HCV) infection. The trial, which will involve 600 adult D.C. residents infected with HCV alone or co-infected with HCV and HIV, also will examine the long-term effects of the treatment.
09 March 2015 | EurekAlert
The West African Ebola outbreak has halted progress in tackling HIV in Sierra Leone, shutting health clinics and scaring patients from being tested or seeking treatment. The United Nations Development Programme (UNDP) has raised concerns that HIV prevalence and drug resistance in the country could increase as a result.
02 March 2015 | Reuters
The European AIDS Treatment Group (EATG), Europe’s network of HIV activists, and AIDES, a leading French NGO in the fight against AIDS and viral hepatitis, backed by 81 European HIV LGBT civil society organisations and concerned actors, issued an urgent HIV Prevention Manifesto today. We demand that pre-exposure prophylaxis for HIV (PrEP) is made available as soon as possible within the European Union, and that Gilead, the company that makes the PrEP medicine Truvada®, submits an application to the European Medicines Agency (EMA) for a change of indication so that its use to prevent HIV can be approved.
25 February 2015 | EATG
The scientific evidence is clear. As a result of extraordinary advances in biomedical research, we now have the tools we need to end the HIV epidemic in the United States. Or do we? According to, "When We Know Better, We Do Better: State of HIV/AIDS Science and Treatment Literacy," a recently released national report by the Black AIDS Institute and others, the missing link to ending the AIDS epidemic in the U.S. is increasing the science and treatment literacy among the non-medical HIV/AIDS workforce.
04 February 2015 | News Medical
Today my HIV comes of age. 18 years ago I was diagnosed HIV positive. If my HIV was a person it could now vote.
03 February 2015 | Speaking Up! (blog)
We, the undersigned, are organizations of people living with hepatitis C virus (HCV), HIV, and our allies. We believe in equitable access to life-saving treatment for all who need it. We write to express our indignation over Gilead’s pricing and licensing policies for the HCV drug, sofosbuvir.
30 January 2015 | Petitionbuzz